NUVB
The table below shows Nuvation Bio Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $5.07M | -$42.63M | -$15.70M | -$19.33M | -$24.93M | -$14.73M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$43.64M | $54.18M | $7.54M | -$52.00M | -$5.55M | -$1.08M |
| Dividends paid | - | - | - | - |
Nuvation Bio Inc. reported operating cash flow of -$173.43M for fiscal year 2025. That is down 33.0% from -$130.41M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$36.53M (FY 2020) to -$173.43M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $44.00K | $548.00K | $21.00K | $298.00K | $4.26M | $624.96M |